FDA.reportPublic FDA data

Lumryz 9 GM Granules for extended release Oral Suspension

RxCUI
2636840
RxNorm name
Lumryz 9 GM Granules for extended release Oral Suspension
Display name
Lumryz 9 GM Granules for extended release Oral Suspension
Full name
Lumryz 9 GM Granules for extended release Oral Suspension
Term type
PSN
Status
DailyMed mapping
Updated
2026-06-04 23:38:47

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
10e5e40c-52f3-4c73-8a34-2c29c690a934Lumryz 9 GM Granules for extended release Oral Suspension [PSN] · sodium oxybate 9000 MG Granules for Oral Suspension [Lumryz] [SBD] · Lumryz 9 GM (equivalent to 7.4 GM oxybate) Granules for Oral Suspension [SY] · Lumryz 9000 MG Granules for Oral Suspension [SY]410These highlights do not include all the information needed to use LUMRYZ™ safely and effectively. See full prescribing information for LUMRYZ. LUMRYZ (sodium oxybate) for extended-release oral suspension, CIII Initial U.S. Approval: 200220251204